Figure 1.
Anti-SARS-CoV-2 nucleocapsid IgG antibody seropositivity, COVID-19 cases and deaths, and population mobility over time
(A) Number of laboratory-confirmed COVID-19 cases according to the Fundação de Vigilância em Saúde do Amazonas (FVS-AM) and crude and test-adjusted anti-SARS-CoV-2 nucleocapsid antibody seropositivity prevalence in the study sample (n=2496) at visits 1 and 2 (grey areas), with error bars showing 95% CIs. SARS-CoV-2 testing rates were low at the beginning of the epidemic and cases were, therefore, substantially subnotified. (B) Confirmed COVID-19-related deaths according to FVS-AM and cemetery-based excess deaths published according to the municipality of Manaus. The number of excess deaths exceeded the number of confirmed deaths during the epidemic because it includes all subnotified COVID-19 deaths as well as non-COVID-19-related deaths due to health system collapse (data extracted by Oliveira from ARPEN civil registry).13, 14 Non-pharmaceutical intervention-related and public health measures and pandemic-related events (marked with vertical lines on the graph) during the SARS-CoV-2 pandemic were collated from the Amazonas state government website. (C) Google mobility data for Manaus city15 plotted as percentage mobility change.